ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 0263

Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus

Stephanie Florez-Pollack1, Syed Rizvi2, Benjamin Chong2 and Linda Hynan2, 1University of Pennsylvania, PHILADELPHIA, PA, 2University of Texas Southwestern Medical Center, Dallas, TX

Meeting: ACR Convergence 2020

Keywords: Cohort Study, Comorbidity, Outcome measures, skin, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little is known about the rates of disease remission and recurrence in patients with CLE.  In this retrospective study, we assessed the rates of remission and recurrence in a longitudinal cohort study of 97 CLE patients, and identified clinical factors associated with each of these outcomes.

Methods: Inclusion criteria included CLE patients with at least three study visits spanning at least six months. The primary outcomes were remission and recurrence of disease activity. The secondary outcomes were time to remission from the baseline visit, and time to recurrence from documented remission. Disease remission was defined as reaching Cutaneous Lupus Erythematosus Activity and Severity Index activity (CLASI-A) equal to 0. Disease recurrence was defined as having a CLASI-A≥1 after remission. Univariate and multivariable analyses were performed to identify clinical and demographic risk factors associated with disease remission and recurrence. Time to remission and recurrence of activity was calculated by survival curve analyses. Significant variables associated with disease remission based on survival curve analyses were then used to perform a Cox proportional hazards model to identify variables that are predictive of shorter time to remission.

Results: 46 patients (48%) reached remission of CLE activity. Median time to remission was 5.45 years from the initial visit. Patients who achieved remission less likely to have discoid lupus erythematosus (DLE) (OR:0.20 (95% CI: 0.05-0.70), p=0.01) and more likely to have milder baseline disease activity (OR:1.75 (1.30-2.38), p< 0.001). Cox proportional hazards regression model showed that the absence of DLE (HR:4.20 (1.98-8.92) and lifetime non-smoker history (HR:2.57 (1.22-5.43)) were predictors of shorter time to remission (Figure 1). 29 patients (63%) of participants experienced disease recurrence within a median of 2.1 years from their remission date. Univariate analyses showed patients with recurrence of CLE activity had a longer disease duration prior to their baseline visit (p=0.002), and were more likely to have DLE (72% v. 29%, p=0.005), but were not significant in the multivariable analyses. 

Conclusion: We found that CLE patients with mild baseline disease activity and do not have DLE are more likely to attain disease remission. The presence of discoid lesions and positive smoking history are associated with longer time to remission on standard-of care therapies. These findings can be helpful for clinicians to guide CLE patients on their potential disease course.

Factors associated with remission of disease activity in patients with cutaneous lupus. Patients without discoid rash (A) (HR:4.20 (1.98-8.92) and without a smoking history (HR:2.57 (1.22-5.43) (B) have a significantly shorter time to disease remission.


Disclosure: S. Florez-Pollack, None; S. Rizvi, None; B. Chong, Viela Bio, 5, Beacon Bioscience, 5, Daavlin Corporation, 2; L. Hynan, None.

To cite this abstract in AMA style:

Florez-Pollack S, Rizvi S, Chong B, Hynan L. Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-disease-activity-remission-and-recurrence-in-cutaneous-lupus-erythematosus/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-disease-activity-remission-and-recurrence-in-cutaneous-lupus-erythematosus/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology